Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands; Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, The Netherlands.
Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
J Thromb Haemost. 2023 Mar;21(3):499-512. doi: 10.1016/j.jtha.2022.11.009. Epub 2022 Dec 22.
Women with rare bleeding disorders (RBDs), including coagulation factor deficiencies and fibrinolytic disorders, may have a higher risk of postpartum hemorrhage (PPH). Information on this patient category is lacking in the existing PPH guidelines because data on PPH in patients with RBDs are scarce.
To describe the prevalence of PPH in women with an RBD and evaluate the use of peripartum hemostatic prophylaxis.
In the Rare Bleeding Disorders in the Netherlands (RBiN) study, patients with RBDs (n = 263) were included from all 6 Dutch hemophilia treatment centers. Patient-reported information on delivery, peripartum hemostatic prophylaxis, and occurrence of PPH was collected retrospectively. If available, information about the precise volume of postpartum blood loss was extracted from electronic patient files. PPH was defined as blood loss ≥500 mL (World Health Organization guideline).
A total of 244 pregnancies, including 193 livebirths, were reported by 85 women. A considerable proportion of these women experienced PPH, ranging from 30% in factor V deficiency to 100% in hyperfibrinolysis. Overall, PPH was reported in 44% of deliveries performed with and 53% of deliveries performed without administration of peripartum hemostatic prophylaxis. Blood loss was significantly higher in deliveries without administration of hemostatic prophylaxis (median 1000 mL) compared to deliveries with administration of prophylaxis (median 400 mL) (p = 0.011). Patients with relatively mild deficiencies also frequently experienced PPH when peripartum hemostatic prophylaxis was omitted.
PPH is common in rare coagulation factor deficiencies, both severe and mild, and fibrinolytic disorders, especially when peripartum prophylactic hemostatic treatment was not administered. The use of prophylactic hemostatic treatment was associated with less postpartum blood loss.
患有罕见出血性疾病(RBD)的女性,包括凝血因子缺乏症和纤维蛋白溶解障碍,可能有更高的产后出血(PPH)风险。由于 RBD 患者的 PPH 数据稀缺,现有的 PPH 指南中缺乏对此类患者群体的信息。
描述 RBD 女性中 PPH 的发生率,并评估围产期止血预防的使用。
在荷兰罕见出血性疾病研究(RBiN)中,从所有 6 个荷兰血友病治疗中心纳入了 263 名 RBD 患者。回顾性收集患者报告的分娩信息、围产期止血预防以及 PPH 的发生情况。如果有,从电子患者档案中提取产后出血量的确切信息。PPH 定义为出血量≥500 mL(世界卫生组织指南)。
共有 85 名女性报告了 244 次妊娠,包括 193 次活产。这些女性中相当一部分经历了 PPH,从因子 V 缺乏症的 30%到纤维蛋白溶解亢进症的 100%不等。总体而言,在未进行围产期止血预防的分娩中,有 44%报告了 PPH,而在进行了预防的分娩中,有 53%报告了 PPH。未进行止血预防的分娩中,出血量明显高于进行了预防的分娩(中位数 1000 mL 比中位数 400 mL)(p=0.011)。即使在未使用围产期止血预防时,相对轻度缺乏症的患者也经常经历 PPH。
在严重和轻度的罕见凝血因子缺乏症以及纤维蛋白溶解障碍中,PPH 很常见,尤其是当未进行围产期预防性止血治疗时。预防性止血治疗的使用与产后出血量较少相关。